A Review of Clinical Effects Associated with Metabolic Syndrome and Exercise in Prostate Cancer Patients

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2016 Jun 29

PMID 27349496

Citations 16

Authors

J L Kiwata

T B Dorff

E T Schroeder

M E Gross

C M Dieli-Conwright

Affiliations

Soon will be listed here.

Abstract

Androgen deprivation therapy (ADT), a primary treatment for locally advanced or metastatic prostate cancer, is associated with the adverse effects on numerous physiologic parameters, including alterations in cardiometabolic variables that overlap with components of the metabolic syndrome (MetS). As MetS is an established risk factor for cardiovascular mortality and treatment for prostate cancer has been associated with the development of MetS, interventions targeting cardiometabolic factors have been investigated in prostate cancer patients to attenuate the detrimental effects of ADT. Much support exists for exercise interventions in improving MetS variables in insulin-resistant adults, but less evidence is available in men with prostate cancer. Regular exercise, when performed at appropriate intensities and volumes, can elicit improvements in ADT-related adverse effects, including MetS, and contributes to the growing body of literature supporting the role of exercise in cancer survivorship. This review (1) discusses the biologic inter-relationship between prostate cancer, ADT and MetS, (2) evaluates the current literature in support of exercise in targeting MetS and (3) describes the physiological mechanisms by which exercise may favorably alter MetS risk factors in prostate cancer patients on ADT.

Citing Articles

From testosterone to mitochondria: unveiling the metabolic consequences of abiraterone therapy.

Lin K, Shao I, Lin Y World J Urol. 2025; 43(1):112.

PMID: 39928129 DOI: 10.1007/s00345-025-05457-z.

Associations between "Cancer Risk", "Inflammation" and "Metabolic Syndrome": A Scoping Review.

Vitale E, Rizzo A, Santa K, Jirillo E Biology (Basel). 2024; 13(5).

PMID: 38785834 PMC: 11117847. DOI: 10.3390/biology13050352.

Effect of resistance training and high-intensity interval training on metabolic parameters and serum level of Sirtuin1 in postmenopausal women with metabolic syndrome: a randomized controlled trial.

Kazemi S, Heidarianpour A, Shokri E Lipids Health Dis. 2023; 22(1):177.

PMID: 37858156 PMC: 10588115. DOI: 10.1186/s12944-023-01940-x.

Nationwide Industry-Led Community Exercise Program for Men With Locally Advanced, Relapsed, or Metastatic Prostate Cancer on Androgen-Deprivation Therapy.

Schumacher O, Galvao D, Taaffe D, Spry N, Hayne D, Tang C JCO Oncol Pract. 2022; 18(8):e1334-e1341.

PMID: 35584353 PMC: 9377716. DOI: 10.1200/OP.21.00745.

Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer.

Nasser N Cancers (Basel). 2022; 14(8).

PMID: 35454866 PMC: 9029515. DOI: 10.3390/cancers14081959.

References

Ouchi N, Parker J, Lugus J, Walsh K . Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011; 11(2):85-97. PMC: 3518031. DOI: 10.1038/nri2921. View

Eckel R, Grundy S, Zimmet P . The metabolic syndrome. Lancet. 2005; 365(9468):1415-28. DOI: 10.1016/S0140-6736(05)66378-7. View

Dockery F, Bulpitt C, Agarwal S, Donaldson M, Rajkumar C . Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003; 104(2):195-201. DOI: 10.1042/CS20020209. View

Smith M, Lee H, Nathan D . Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91(4):1305-8. DOI: 10.1210/jc.2005-2507. View

Cormie P, Galvao D, Spry N, Joseph D, Chee R, Taaffe D . Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2014; 115(2):256-66. DOI: 10.1111/bju.12646. View

Smith J, Bennett S, Evans L, Kynaston H, Parmar M, Mason M . The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001; 86(9):4261-7. DOI: 10.1210/jcem.86.9.7851. View

DAmico A, Braccioforte M, Moran B, Chen M . Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 77(5):1329-37. DOI: 10.1016/j.ijrobp.2009.06.051. View

Bateman L, Slentz C, Willis L, Shields A, Piner L, Bales C . Comparison of aerobic versus resistance exercise training effects on metabolic syndrome (from the Studies of a Targeted Risk Reduction Intervention Through Defined Exercise - STRRIDE-AT/RT). Am J Cardiol. 2011; 108(6):838-44. PMC: 3752599. DOI: 10.1016/j.amjcard.2011.04.037. View

Pedersen B, Febbraio M . Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012; 8(8):457-65. DOI: 10.1038/nrendo.2012.49. View

10.

Buschemeyer 3rd W, Freedland S . Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007; 52(2):331-43. DOI: 10.1016/j.eururo.2007.04.069. View

11.

Johnson J, Slentz C, Houmard J, Samsa G, Duscha B, Aiken L . Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise). Am J Cardiol. 2007; 100(12):1759-66. PMC: 2190779. DOI: 10.1016/j.amjcard.2007.07.027. View

12.

Eri L, Urdal P, Bechensteen A . Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol. 1995; 154(1):100-4. View

13.

Braun S, Bitton-Worms K, LeRoith D . The link between the metabolic syndrome and cancer. Int J Biol Sci. 2011; 7(7):1003-15. PMC: 3164150. DOI: 10.7150/ijbs.7.1003. View

14.

Hvid T, Winding K, Rinnov A, Dejgaard T, Thomsen C, Iversen P . Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocr Relat Cancer. 2013; 20(5):621-32. DOI: 10.1530/ERC-12-0393. View

15.

Carey A, Steinberg G, Macaulay S, Thomas W, Holmes A, Ramm G . Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes. 2006; 55(10):2688-97. DOI: 10.2337/db05-1404. View

16.

Braga-Basaria M, Dobs A, Muller D, Carducci M, John M, Egan J . Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006; 24(24):3979-83. DOI: 10.1200/JCO.2006.05.9741. View

17.

Katzmarzyk P, Leon A, Wilmore J, Skinner J, Rao D, Rankinen T . Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med Sci Sports Exerc. 2003; 35(10):1703-9. DOI: 10.1249/01.MSS.0000089337.73244.9B. View

18.

Storer T, Miciek R, Travison T . Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl. 2012; 14(2):204-21. PMC: 3735097. DOI: 10.1038/aja.2011.104. View

19.

Yu H, Rohan T . Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000; 92(18):1472-89. DOI: 10.1093/jnci/92.18.1472. View

20.

Pollak M . Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab. 2008; 22(4):625-38. DOI: 10.1016/j.beem.2008.08.004. View